RajivP.PanikkarMD

Oncology • Danville, PA

Director, Medical Oncology, Geisinger Medical Center

Join to view full profile

Dr. Panikkar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Panikkar's full profile

Already have an account?

Office
100 N Academy Ave
Danville, PA 17822
Phone+1 570-271-6045

Fax+1 570-271-6542
Is this information wrong?

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2001 - 2004
University of Pittsburgh School of MedicineClass of 2001

Certifications & Licensure

PA State Medical License 2003 - 2024
VA State Medical License 2001 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 17
Completed
Phase 2
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2010 Sep 17
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Evaluating the Cologuard Test for Use in Lynch Syndrome Start of enrollment: 2021 Nov 01
Withdrawn
Join now to see all

Publications & Presentations

PubMed

9 citations
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on o...
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zor...> ;The Lancet. Oncology. 2023 Sep 1
1 citations
Radiation Therapy in the Last Month of Life: Association With Aggressive Care at the End of Life.
Mellar P Davis, Erin Vanenkevort, Amanda Young, Mark Wojtowicz, Mudit Gupta, Braxton Lagerman, Edward Liu, Heath Mackley, Rajiv Panikkar> ;Journal of Pain and Symptom Management. 2023 Dec 1
Validation of the Surprise Question and the Development of a Multivariable Model.
Mellar Davis, Erin Vanenkevort, Amanda Young, Mark Wojtowicz, Braxton Lagerman, Mudit Gupta, Christian Adonizio, Rajiv Panikkar> ;Journal of Pain and Symptom Management. 2023 May 1
7 citations
The Financial Impact of Palliative Care and Aggressive Cancer Care on End-of-Life Health Care Costs.
Mellar P Davis, Erin A Vanenkevort, Alexander Elder, Amanda Young, Irina D Correa Ordonez, Mark J Wojtowicz, Halle Ellison, Carlos Fernandez, Zankhana Mehta, Bertrand ...> ;The American Journal of Hospice & Palliative Care. 2023 Jan 1
5 citations
When does early palliative care influence aggressive care at the end of life?
Mellar P Davis, Erin A Vanenkevort, Alexander Elder, Amanda Young, Irina D Correa Ordonez, Mark J Wojtowicz, Halle Ellison, Carlos Fernandez, Zankhana Mehta, Bertrand ...> ;Supportive Care in Cancer. 2022 Jun 1
2 citations
Organizational Characteristics and Smoking Cessation Support in Community-Based Lung Cancer Screening Programs.
Christina Bellinger, Kristie Long Foley, Emily V Dressler, Carol Kittel, David P Miller Jr, Kathryn E Weaver, Erin L Sutfin, W Jeffrey Petty, John Spangler, Rebecca St...> ;Journal of the American College of Radiology. 2022 Apr 1
2 citations
Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy.
Na Tosha Gatson, Mina Makary, Shane Bross, Joseph Vadakara, Tristan Maiers, Gino Mongelluzzo, Erika Leese, Cameron Brimley, Ekokobe Fonkem, Anand Mahadevan, Atom Sarka...> ;Neuro-Oncology Practice. 2021 May 26
14 citations
Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards.
, , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2020 Feb 20
86 citations
Sarcopenia associated with chemotherapy and targeted agents for cancer therapy.
Mellar P. Davis, Rajiv Panikkar> ;Annals of Palliative Medicine. 2019 Jan 1
8 citations
Checkpoint Inhibitors, Palliative Care, or Hospice.
Mellar P. Davis, Rajiv Panikkar> ;Current Oncology Reports. 2018 Jan 19
6 citations
The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Rajiv P. Panikkar, Igor Astsaturov, Corey J. Langer> ;Cancer Investigation. 2008 Feb 1
46 citations
Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with oc...
Sanjiv S. Agarwala, Rajiv Panikkar, John M. Kirkwood> ;Melanoma Research. 2004 Jun 1
Join now to see all